Inhibition of 5-LOX by MK886 resultsin activation of PPARγ in breast and lung cancer cell lines [9, 21].Inhibition of COX-2 by celecoxib reduces PGE2 production, downregulates cPLA2α expression in lung cancer cell lines,but also induces PPARγ expression and activity [73, 74].On the other hand, PPARγ ligand ciglitazone may modulate COX-2 expression andPGE2 production through a PPARγ-independent mechanism. Here, ALOX5 is linked to lung cancer.